HHCP
RPRX icon

Hilton Head Capital Partners’s Royalty Pharma RPRX Stock Holding History

Hilton Head Capital Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$280 Hold
5
– – ﹤0.01% 887
2026
Q1 		$240 Hold
5
– – ﹤0.01% 949
2025
Q4 		$193 Buy
+5
New +$191 ﹤0.01% 897

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hilton Head Capital Partners's RPRX Position: Q2 2026 in Review

Hilton Head Capital Partners held its Royalty Pharma (RPRX) position steady in Q2 2026 at 5 shares worth $280. The position accounts for ﹤0.01% of the portfolio, ranked #887.

Hilton Head Capital Partners first reported a position in RPRX in Q4 2025 and has held it in 3 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Hilton Head Capital Partners held 5 shares of Royalty Pharma worth $280 as of Q2 2026.
  • Hilton Head Capital Partners left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up ﹤0.01% of Hilton Head Capital Partners's portfolio in Q2 2026, its #887 holding.
  • Hilton Head Capital Partners first reported a position in Royalty Pharma in Q4 2025 and has held it in 3 quarters since.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.